Business Description
Exicure, Inc. is a biotechnology firm that utilizes its unique spherical nucleic acid (SNA) platform to create therapies for neurological conditions and hair loss. Its primary experimental candidate, SCN9A, is currently undergoing preclinical evaluation for addressing neuropathic and chronic pain. The company has entered into a strategic partnership with AbbVie Inc. to advance SNA-based solutions for various hair loss conditions, under a collaboration, option, and license agreement. Additionally, a separate collaborative effort with Ipsen S.A. aims to investigate, develop, and commercialize novel spherical nucleic acids targeting Huntington's disease and Angelman syndrome. Established in 2011, Exicure's corporate base is located in Chicago, Illinois.
Business History
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -0.79
Total Equity: $3.93M
Shares: 6,297,094
Total Debt: $176,000
Cash: $3.75M
EBITDA: -$5.12M
Total Debt: $176,000
Cash: $3.75M
Revenue: $0.00
Shares: 6,297,094
Revenue: $0.00
Revenue: $0.00
Revenue: $0.00
Total Equity: $3.93M
Tax Rate: 11.4%
Equity: $3.93M
Total Debt: $176,000
Cash: $3.75M
Current Liabilities: $3.89M
Long-Term Debt: $0.00
Total Debt: $176,000
Total Equity: $3.93M
Shares: 6,297,094
Shares: 6,297,094
CapEx: -$1,000
Shares: 6,297,094
Stock Price: $2.70
Net Income: -$4.95M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 26, 2026 1:49pm (20h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $-483,000 | $28.8M | $0 | $500,000 | $0 |
| Cost of Revenue | $0 | $1.9M | $1.4M | $0 | $460,000 |
| Gross Profit | $-483,000 | $27.0M | -$1.4M | $500,000 | $-460,000 |
| Operating Expenses | $62.1M | $28.8M | $13.6M | $12.7M | $9.7M |
| Operating Income | -$62.5M | -$1.8M | -$15.0M | -$12.2M | -$10.1M |
| Net Income | -$64.1M | -$2.6M | -$16.9M | -$9.7M | -$4.9M |
| EBITDA | -$60.6M | $78,000 | -$15.5M | -$8.9M | -$5.1M |
| EPS | $-21.70 | $-0.56 | $-2.11 | $-1.59 | $-0.79 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 26, 2026 1:49pm (20h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $34.6M | $8.6M | $816,000 | $12.5M | $3.7M |
| Total Current Assets | $43.7M | $10.1M | $2.0M | $13.7M | $4.6M |
| Total Assets | $64.9M | $23.3M | $11.6M | $15.1M | $14.0M |
| Current Liabilities | $34.1M | $1.6M | $2.5M | $3.1M | $3.9M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $53.6M | $8.4M | $8.5M | $8.3M | $10.1M |
| Total Equity | $11.2M | $14.9M | $3.0M | $6.8M | $3.9M |
| Retained Earnings | -$170.1M | -$172.6M | -$189.6M | -$199.3M | -$204.2M |
Cash Flow (Annual)
Last updated: Jun 26, 2026 1:49pm (20h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$34.8M | -$35.7M | -$10.4M | -$2.9M | -$8.6M |
| Capital Expenditure | $-968,000 | $-10,000 | $0 | $0 | $-1,000 |
| Free Cash Flow | -$35.8M | -$35.7M | -$10.4M | -$2.9M | -$8.6M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | -$1.8M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $9.4M | -$34.1M | -$7.8M | $10.5M | -$8.8M |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 1:49pm (20h ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue |
$12.8M $7.9M – $17.7M
|
$16.7M $16.7M – $16.7M
|
$28.9M $28.9M – $28.9M
|
$63.2M $63.2M – $63.2M
|
| EBITDA |
$6,927 $4,260 – $9,594
|
$9,028 $9,028 – $9,028
|
$11.6M $11.6M – $11.6M
|
$25.3M $25.3M – $25.3M
|
| Net Income |
-$146.8M -$146.8M – -$146.8M
|
-$677.6M -$677.6M – -$677.6M
|
-$699.0M -$699.0M – -$699.0M
|
-$491.2M -$491.2M – -$491.2M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 26, 2026 1:49pm (20h ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +6,068.1% | -100.0% | — | -100.0% |
| Gross Profit Growth | +5,683.9% | -105.3% | +135.1% | -192.0% |
| Operating Income Growth | +97.1% | -719.0% | +18.4% | +17.3% |
| Net Income Growth | +96.0% | -555.1% | +42.6% | +49.0% |
| EBITDA Growth | +100.1% | -20,021.8% | +43.0% | +42.2% |
Narrative Economics
market-narrative step).